Roman Gulati

发表

ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS.

Ruth Etzioni, Jane M Lange, Roman Gulati, 2018, The annals of applied statistics.

Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.

Ruth Etzioni, Iris Lansdorp-Vogelaar, Marjolein van Ballegooijen, 2014, Annals of internal medicine.

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context.

Angela Mariotto, Ruth Etzioni, Eric Feuer, 2009, Journal of the National Cancer Institute.

Projecting Benefits and Harms of Novel Cancer Screening Biomarkers: A Study of PCA3 and Prostate Cancer

Yair Lotan, Ziding Feng, Ruth Etzioni, 2015, Cancer Epidemiology, Biomarkers & Prevention.

Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer.

Roman Gulati, C. Higano, Rachel Hunter-Merrill, 2015, Clinical genitourinary cancer.

Recent Trends in PSA Testing and Prostate Cancer Incidence: A Look at Context.

Ruth Etzioni, Roman Gulati, Ruth Etzioni, 2016, JAMA oncology.

Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.

Donatello Telesca, Roman Gulati, P. Nelson, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

Hamid Bolouri, Jay Shendure, Min Fang, 2016 .

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

Ahmet Zehir, Levi Garraway, Colin C Pritchard, 2016, The New England journal of medicine.

What If I Don't Treat My PSA-Detected Prostate Cancer? Answers from Three Natural History Models

Eveline A M Heijnsdijk, Harry J de Koning, Lurdes Y T Inoue, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Long-term dynamics of bone mineral density during intermittent androgen deprivation for men with nonmetastatic, hormone-sensitive prostate cancer.

Roman Gulati, C. Higano, E. Yu, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quantifying the role of PSA screening in the US prostate cancer mortality decline

Dante diTommaso, Seth Falcon, Angela Mariotto, 2008, Cancer Causes & Control.

Comparative Effectiveness of Alternative Prostate-Specific Antigen–Based Prostate Cancer Screening Strategies

Ruth Etzioni, Roman Gulati, Ruth Etzioni, 2013, Annals of Internal Medicine.

Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials

Yu Shen, Marisa C Eisenberg, Marc D Ryser, 2018, American journal of epidemiology.

Impact of PSA Screening on the Incidence of Advanced Stage Prostate Cancer in the United States: A Surveillance Modeling Approach

Seth Falcon, Ruth Etzioni, Roman Gulati, 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data

Martin Eklund, Andreas Karlsson, Alexandra Jauhiainen, 2018, bioRxiv.